Turning Microalgae-Derived Extracellular Vesicles Into a Next-Generation Drug Delivery Platform
Paris-based AGS Therapeutics (AGS), which is focused on turning microalgae-derived extracellular vesicles (MEVs) into a next-generation drug delivery platform, signed an agreement with INITS SMO, a GMP-qualified shared manufacturing organization (SMO) also in France, to support the transition of its MEV manufacturing activities to full GMP compliance and enable the production of its first clinical-grade MEV batches.
- Genetic Engineering & Biotechnology News.
